Trigran Investments Inc. Sells 689,430 Shares of MiMedx Group, Inc $MDXG

Trigran Investments Inc. reduced its holdings in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 8.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,701,028 shares of the company’s stock after selling 689,430 shares during the quarter. MiMedx Group accounts for about 9.7% of Trigran Investments Inc.’s holdings, making the stock its 3rd biggest position. Trigran Investments Inc. owned approximately 5.20% of MiMedx Group worth $53,753,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Royal Bank of Canada grew its position in MiMedx Group by 1.4% in the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after purchasing an additional 13,629 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after buying an additional 4,296 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of MiMedx Group during the 1st quarter valued at $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares during the period. Finally, Millennium Management LLC raised its stake in MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after acquiring an additional 596,016 shares during the period. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

MiMedx Group stock opened at $4.75 on Friday. MiMedx Group, Inc has a 1-year low of $4.70 and a 1-year high of $8.20. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $705.69 million, a PE ratio of 14.84 and a beta of 1.60. The firm’s 50 day simple moving average is $5.52 and its 200 day simple moving average is $6.51.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. As a group, analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on MDXG. Mizuho reduced their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. UBS Group set a $10.00 price objective on shares of MiMedx Group in a report on Monday, February 23rd. Lake Street Capital reduced their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Finally, Citigroup initiated coverage on MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.60.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.